Risankizumab, a humanized monoclonal antibody targeting interleukin-23, is efficacious in treating moderate to severe plaque psoriasis and psoriatic arthritis but carries potential risks of uncommon adverse effects, including drug-induced thrombocytopenia. The gene discussed is IL37; the disease is psoriasis vulgaris.